person · Reporting owner

WEATHERMAN ELIZABETH H

Disclosed activity across 6 companies

Tapewire entity: 40507
SEC CIK: 0001188681

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INSULET CORPPODD · Entity 3516	Director	June 03, 2026	June 03, 2026
Royalty Pharma plcRPRX · Entity 3100	Director	June 05, 2026	June 08, 2026
VAPOTHERM INCVAPO · Entity 87270	Director	September 20, 2024	September 24, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSULET CORP

Report date June 03, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,352	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Purchase · Acquired 3,450 · Balance 10,352 F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69. F2: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69.

F2: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Royalty Pharma plc

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	13,103	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 13,103 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

VAPOTHERM INC

Report date September 20, 2024 · Filed September 24, 2024

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-20 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2024-09-20 · Disposition to issuer · Disposed 14,555 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-20 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2024-09-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.
Common StockSEC Table I · non-derivative	IndirectElizabeth H. Weatherman Revocable Trust	Reported balance After 2024-09-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-09-20 · Disposition to issuer · Disposed 81,546 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $150.00 · Expires 2029-07-24	Direct	Reported balance After 2024-09-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-20 · Disposition to issuer · Disposed 1,187 · Balance 0 F3: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2032-07-27	Direct	Reported balance After 2024-09-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-09-20 · Disposition to issuer · Disposed 1,089 · Balance 0 F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.

F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.

F3: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NEVRO CORP

Report date April 03, 2025 · Filed April 03, 2025

Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-04-03 transaction · row 1 1 source row Row 1 · 2025-04-03 · Disposition to issuer · Disposed 86,171 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").

F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.

Silk Road Medical Inc

Report date September 17, 2024 · Filed September 19, 2024

Section 16 reporting ended · disclosed 2024-09-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-17 transaction · row 1 1 source row Row 1 · 2024-09-17 · Disposition to issuer · Disposed 155,004 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2026-08-04	Direct	Reported balance After 2024-09-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-09-17 · Disposition to issuer · Disposed 35,185 · Balance 0 F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2029-04-03	Direct	Reported balance After 2024-09-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-09-17 · Disposition to issuer · Disposed 8,910 · Balance 0 F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Wright Medical Group N.V.

Report date November 11, 2020 · Filed November 13, 2020

Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	Reported balance After 2020-11-11 transaction · row 1 1 source row Row 1 · 2020-11-11 · Other · Disposed 38,084 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26	Direct	Reported balance After 2020-11-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24	Direct	Reported balance After 2020-11-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25	Direct	Reported balance After 2020-11-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-11 · Disposition to issuer · Disposed 10,275 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19	Direct	Reported balance After 2020-11-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).

F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 8, 2026 20:29 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	4,545	$0.00	$0.00	Disclosure SEC source: 0001188681-26-000003 · wk-form4_1780950541.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,103 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
June 03, 2026 Filed Jun 3, 2026 20:19 UTC	INSULET CORP PODD · Entity 3516	PurchaseCommon Stock	3,450	$144.20	$497,490.00	Disclosure SEC source: 0001145197-26-000138 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,352 F1 · price: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69. F2 · price: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 20, 2026 Filed May 21, 2026 20:40 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,660	$0.00	$0.00	Disclosure SEC source: 0001145197-26-000129 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,902 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. Read SEC document
July 31, 2025 Filed Aug 1, 2025 00:45 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	5,806	$0.00	$0.00	Disclosure SEC source: 0001802768-25-000090 · wk-form4_1754009123.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,558 F2 · shares: Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
July 31, 2025 Filed Aug 1, 2025 00:45 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	2,752	$0.00	$0.00	Disclosure SEC source: 0001802768-25-000090 · wk-form4_1754009123.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,752 F1 · shares: Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
May 22, 2025 Filed May 27, 2025 20:14 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	778	$0.00	$0.00	Disclosure SEC source: 0001127602-25-015664 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,242 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2026. Read SEC document
April 03, 2025 Filed Apr 3, 2025 16:30 UTC	NEVRO CORP NVRO · Entity 12422	Disposition to issuerCommon Stock	86,171	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-050462 · ownership.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document
December 31, 2024 Filed Jan 2, 2025 16:50 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	5,325	$0.00	$0.00	Disclosure SEC source: 0001444380-25-000002 · wk-form4_1735854645.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,171 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 19,169 restricted stock units. Read SEC document
September 30, 2024 Filed Oct 2, 2024 16:58 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	3,544	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000500 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,846 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 19,169 restricted stock units. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:55 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerStock Option (right to buy) · Derivative	1,089	$0.00 Strike: $18.48	$0.00	Disclosure SEC source: 0001235802-24-000078 · primary_doc.xml · derivative · entry 5 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,089 shares Expires 2032-07-27 F4 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:55 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerStock Option (right to buy) · Derivative	1,187	$0.00 Strike: $150.00	$0.00	Disclosure SEC source: 0001235802-24-000078 · primary_doc.xml · derivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,187 shares Expires 2029-07-24 F3 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:55 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerCommon Stock	81,546	$2.18	$177,770.28	Disclosure SEC source: 0001235802-24-000078 · primary_doc.xml · nonDerivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:55 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerCommon Stock	3,000	$2.18	$6,540.00	Disclosure SEC source: 0001235802-24-000078 · primary_doc.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:55 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerCommon Stock	14,555	$2.18	$31,729.90	Disclosure SEC source: 0001235802-24-000078 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:08 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerStock Option (right to buy) · Derivative	8,910	$7.50 Strike: $20.00	$66,825.00	Disclosure SEC source: 0001140361-24-041429 · form4.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,910 shares Expires 2029-04-03 F5 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:08 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerStock Option (right to buy) · Derivative	35,185	$25.90 Strike: $1.60	$911,291.50	Disclosure SEC source: 0001140361-24-041429 · form4.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,185 shares Expires 2026-08-04 F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:08 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerCommon Stock	155,004	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-041429 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2 · price: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3 · price: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. Read SEC document
June 30, 2024 Filed Jul 2, 2024 16:10 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	2,353	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000381 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,302 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 19,169 restricted stock units. Read SEC document
June 18, 2024 Filed Jun 21, 2024 22:48 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	5,859	$0.00	$0.00	Disclosure SEC source: 0001593968-24-000886 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,004 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
May 23, 2024 Filed May 28, 2024 18:54 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	19,169	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000262 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,949 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 23, 2024 or (ii) the next Annual Meeting following May 23, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 19,169 RSUs. Read SEC document
May 22, 2024 Filed May 23, 2024 21:16 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,380	$0.00	$0.00	Disclosure SEC source: 0001127602-24-016468 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,464 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2025 and are settled in shares of common stock on a one-for-one basis. Read SEC document
March 31, 2024 Filed Apr 2, 2024 19:05 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	1,372	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000201 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,780 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:52 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	6,000	$10.00	$60,000.00	Disclosure SEC source: 0001235802-24-000012 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,555 F1 · shares: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2024. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F1 · price: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2024. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F2 · balance_after: Includes 8,625 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. F3 · balance_after: On August 18, 2023, a 1-for-8 reverse split of the common stock of Vapotherm, Inc. occurred resulting in a decrease in the number of shares held by the reporting person. In addition, proportionate adjustments have been made to the reporting person's outstanding equity awards, including the number of restricted stock units as reflected on this Form 4 and described in footnote (2) to this Form 4, to reflect the 1-for-8 reverse stock split. Read SEC document
December 31, 2023 Filed Jan 3, 2024 16:49 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	920	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000003 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,408 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document
September 30, 2023 Filed Oct 3, 2023 16:58 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	1,030	$0.00	$0.00	Disclosure SEC source: 0001610717-23-000304 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,488 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document
July 26, 2023 Filed Jul 28, 2023 21:07 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	21,000	$0.00	$0.00	Disclosure SEC source: 0001235802-23-000084 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,441 F1 · shares: This restricted stock unit was granted under the 2018 Equity Plan and will vest in full on the earlier of the first anniversary of the date of grant or the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. F2 · balance_after: Includes 27,000 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. Read SEC document
June 30, 2023 Filed Jul 5, 2023 17:08 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	779	$0.00	$0.00	Disclosure SEC source: 0001610717-23-000197 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,458 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document
June 21, 2023 Filed Jun 23, 2023 21:44 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantOption (right to buy) · Derivative	3,114	$0.00 Strike: $33.57	$0.00	Disclosure SEC source: 0001593968-23-001040 · primary_01.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,114 Underlying: Common Stock · 3,114 shares Expires 2033-06-21 F2 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F3 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2023, December 5, 2023, March 5, 2024, and the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 21, 2023 Filed Jun 23, 2023 21:44 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	4,691	$0.00	$0.00	Disclosure SEC source: 0001593968-23-001040 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,145 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
May 25, 2023 Filed May 30, 2023 17:26 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	6,754	$0.00	$0.00	Disclosure SEC source: 0001610717-23-000079 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,679 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2023 or (ii) the next Annual Meeting following May 25, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 6,754 RSUs. Read SEC document
May 23, 2023 Filed May 24, 2023 20:17 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	843	$0.00	$0.00	Disclosure SEC source: 0001127602-23-016721 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,084 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. Read SEC document
April 17, 2023 Filed Apr 19, 2023 22:14 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	5,000	$41.91	$209,550.00	Disclosure SEC source: 0001593968-23-000629 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,454 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 22, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document
March 31, 2023 Filed Apr 4, 2023 16:46 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	548	$0.00	$0.00	Disclosure SEC source: 0001140361-23-016295 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,925 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document
March 15, 2023 Filed Mar 17, 2023 23:06 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	5,000	$41.91	$209,550.00	Disclosure SEC source: 0001593968-23-000496 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,454 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on November 22, 2022. Read SEC document
February 15, 2023 Filed Feb 17, 2023 23:56 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	5,000	$49.86	$249,300.00	Disclosure SEC source: 0001593968-23-000338 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,454 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on November 22, 2022. Read SEC document
February 10, 2023 Filed Feb 14, 2023 21:54 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseWarrant · Derivative	476,190	Not disclosed Strike: $1.17	Not disclosed	Disclosure SEC source: 0001235802-23-000021 · primary_doc.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 476,190 Underlying: Common Stock · 476,190 shares Expires 2028-02-10 F1 · price: $1.05 per unit, each unit consisted of one share of common stock and a warrant to purchase one share of common stock. Read SEC document
February 10, 2023 Filed Feb 14, 2023 21:54 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseCommon Stock	476,190	$1.05	$499,999.50	Disclosure SEC source: 0001235802-23-000021 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 652,372 F1 · price: $1.05 per unit, each unit consisted of one share of common stock and a warrant to purchase one share of common stock. Read SEC document
January 17, 2023 Filed Jan 19, 2023 23:44 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	56,355	$54.69	$3,082,224.02	Disclosure SEC source: 0001593968-23-000178 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,454 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on November 22, 2022. F2 · price: This transaction was executed in multiple trades at price ranging from $53.84 to $57.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 02, 2023 Filed Jan 4, 2023 23:16 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	12,000	$2.70	$32,400.00	Disclosure SEC source: 0001235802-23-000009 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,441 F1 · shares: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2023. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F1 · price: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2023. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F2 · balance_after: Includes 12,000 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. Read SEC document
December 30, 2022 Filed Jan 4, 2023 16:38 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	500	$0.00	$0.00	Disclosure SEC source: 0001567619-23-000254 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,377 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document
December 05, 2022 Filed Dec 7, 2022 21:35 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseCommon Stock	10,423	$1.56	$16,283.85	Disclosure SEC source: 0001235802-22-000133 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 176,182 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.60, inclusive. The reporting person undertakes to provide to Vapotherm, Inc., any security holder of Vapotherm, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
December 02, 2022 Filed Dec 6, 2022 21:38 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseCommon Stock	89,229	$1.51	$134,494.87	Disclosure SEC source: 0001235802-22-000132 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 165,759 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.48 to $1.55, inclusive. The reporting person undertakes to provide to Vapotherm, Inc., any security holder of Vapotherm, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
September 30, 2022 Filed Oct 4, 2022 17:48 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	425	$0.00	$0.00	Disclosure SEC source: 0001567619-22-018217 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,877 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document
September 15, 2022 Filed Sep 19, 2022 22:34 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	5,000	$42.45	$212,250.00	Disclosure SEC source: 0001593968-22-001450 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,809 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 10, 2022. Read SEC document
September 15, 2022 Filed Oct 6, 2022 00:51 UTC Amendment	Silk Road Medical Inc SILK · Entity 87417	OtherCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001593968-22-001503 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,809 F1 · kind: On September 15, 2022, the Reporting Persons broker reported a sale of 5,000 shares under the Reporting Persons Rule 10b5-1 Trading Plan that was unable to be settled due to failure to receive required paperwork and as a result such sale was subsequently rescinded. F1 · price: On September 15, 2022, the Reporting Persons broker reported a sale of 5,000 shares under the Reporting Persons Rule 10b5-1 Trading Plan that was unable to be settled due to failure to receive required paperwork and as a result such sale was subsequently rescinded. Read SEC document
August 15, 2022 Filed Aug 17, 2022 21:33 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	5,000	$47.25	$236,250.00	Disclosure SEC source: 0001593968-22-001350 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,809 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 10, 2022. Read SEC document
August 08, 2022 Filed Aug 9, 2022 22:25 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	8,645	$49.91	$431,471.95	Disclosure SEC source: 0001593968-22-001318 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,809 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 10, 2022. Read SEC document
July 27, 2022 Filed Aug 4, 2022 20:58 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantStock Option (right to buy) · Derivative	8,717	$0.00 Strike: $2.31	$0.00	Disclosure SEC source: 0001235802-22-000088 · primary_doc.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,717 Underlying: Common Stock · 8,717 shares Expires 2032-07-27 F2 · derivative.exercise_date: This option was granted under the 2018 Equity Plan and will vest in full on the earlier of the first anniversary of the date of grant or the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. Read SEC document
July 21, 2022 Filed Jul 25, 2022 22:00 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	5,000	$41.91	$209,550.00	Disclosure SEC source: 0001593968-22-001265 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,454 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 10, 2022. Read SEC document
July 08, 2022 Filed Jul 11, 2022 23:09 UTC	Silk Road Medical Inc SILK · Entity 87417	SaleCommon Stock	10,000	$41.91	$419,100.00	Disclosure SEC source: 0001593968-22-001240 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,454 F1 · kind: The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 10, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.